Lonza Grp receives Investment Bank Analyst Rating Update
Markets await inflation data for clues ahead of Fed response US Dollar, Treasuries rally Gold falters Key EventsDespite the expectation that the Biden Administration’s...
Txcell (PA:TXCL) has announced that Lonza Group AG (SIX:LONN), the biopharmaceutical and cell manufacturing global specialist, will produce its CAR Tregs. TxCell uses a robust...
Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life science industries. The Company's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The Company divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech comprises the Company's Biologics, Small-Molecule, and Consumables and Research Tools businesses. The segment includes mammalian, microbial, chemical, bioconjugates, cell and gene therapy technology platforms. The Specialty Ingredients segment focuses on anti-microbial applications within Consumer Health division, which covers hygiene, nutrition and personal care products, as well as preservatives, capsules and food supplements, among others, and Consumer & Resources Protection division, which includes coatings and composites, and agro ingredients.
|Average||668.47 (+13.92% Upside)|
|No. of Analysts||15|